On the stock market since 1995, it operates in the world of health and science. It has 25,000 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (2% a year).
The gap is $3.5B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price looks reasonable next to what the company earns.
There is growth, but not at top-of-the-class tempo.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
Over the last 3 years, sales grew only 1% a year on average. At this size, speeding back up is not easy.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 27/100.
Costs swallow the gains that sales growth brings in.
On our five-subject report card, HSIC sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: HSIC is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.